Durvalumab as Consolidation Therapy in Post-Multimodal Interventional Treatment for Patients with Advanced Solid Tumors: A Preliminary Study

Figure 3

Comparative analysis of Progression-Free Survival (PFS) rate (%) for different antibodies.